Tafluprost

CAS No. 209860-87-7

Tafluprost( AFP-168,MK2452 )

Catalog No. M22166 CAS No. 209860-87-7

Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 46 In Stock
5MG 71 In Stock
10MG 87 In Stock
25MG 143 In Stock
50MG 210 In Stock
100MG 311 In Stock
500MG 749 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tafluprost
  • Note
    Research use only, not for human use.
  • Brief Description
    Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
  • Description
    Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma.
  • In Vitro
    Cell Viability Assay Cell Line:RGC Concentration:0.1, 1, 3, 10, 100 μM Incubation Time:48 h Result:Enhanced the viability of these cells in a dose-dependent fashion, with an optimal concentration of 3μM.Increased the relative fluorescence intensity (RFI).
  • In Vivo
    Animal Model:Male Sprague rat model Dosage:0.0015% Administration:Via eye drops Result:Increased the number of RGCs and reduced the number of TUNEL-positive cells.Animal Model:Prostaglandin receptor deletion C57BL/6 mice model Dosage:3 μL (0.0015% Tafluprost)Administration:Instillation; Single dose Result:Reduced IOP in WT, EP1KO, EP2KO, EP3KO and FPKO mice, and the average IOP reduction rates were 25.8(2.1)%, 26.3(0.8)%, 24.2(1.4)%, 16.5(1.7)% and 20.9(1.5)%, respectively. (The decrease of IOP in EP3KO and FPKO mice was less than that in WT mice.)
  • Synonyms
    AFP-168,MK2452
  • Pathway
    GPCR/G Protein
  • Target
    Prostaglandin Receptor
  • Recptor
    PGF2α
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    209860-87-7
  • Formula Weight
    452.53
  • Molecular Formula
    C25H34F2O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (552.45 mM)
  • SMILES
    CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.
molnova catalog
related products
  • Nestorone

    Nestoron2 (ST1435, Elcometrine) is a 19-norprogesterone derivative and steroidal progestin which is used as a hormonal contraceptive, a high-affinity agonist of the progesterone receptor.

  • TG6-129

    TG6-129 is an antagonist of the EP2 receptor. TG6-129 suppresses PGE2-induced elevation of cAMP in cells expressing EP2 with an IC50 value of 1.6 μM.

  • ONO-AE3-208

    ONO-AE3-208 is an EP4 antagonist. It suppresses cell migration, invasion, and metastasis of prostate cancer.